Kevin Eggan, Ph.D., joined 澳门正规博彩十大排行平台 in October 2020 and serves as Group Vice President, Head of Research and Early Development. He is responsible for the execution of 澳门正规博彩十大排行平台’s discovery research programs, helping to shape the vision and long-term growth of our company through the oversight of an exceptional research pipeline of first- or best-in-class therapies.
Prior to joining 澳门正规博彩十大排行平台, Dr. Eggan served as a tenured Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Director of Stem Cell Biology for the Stanley Center for Psychiatric Research at the Broad Institute, and an Institute Member of the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard.
Dr. Eggan earned a B.S. degree in microbiology and immunology from the University of Illinois and a Ph.D. in biology from MIT, where he focused on cloning, stem cells and reprogramming after nuclear transfer under the guidance of genetics pioneer Rudolf Jaenisch, Ph.D. He remained in the Jaenisch lab for a one-year post-doctoral position at the Whitehead Institute for Biomedical Research, where he conducted a study with Nobel laureate Richard Axel, M.D.
Dr. Eggan has published 130 scientific articles and holds 13 patents. He received the MacArthur Foundation’s “Genius Grant” and was named one of 50 Howard Hughes Medical Institute Early Career Scientists, among other distinctions. In addition, Dr. Eggan has served on the Scientific Advisory Boards of Ipierian, Roche and Angelini Pharma.
We maximize the impact of genetic innovation to develop transformative therapies.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.
Learn More Our Pipeline ⌃